Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus - Seite 2

The ongoing testing of stenoparib at the at the Pathogen and Microbiome Institute is part of the first steps of a potential therapeutic expansion of this drug, an orally administered phase 2 anticancer agent, to anti-viral applications.  Stenoparib is one of very few drugs that have been reported, based on ongoing or completed pre-clinical tests, as a potential treatment for patients infected with SARS-Cov-2 or the B.1.1.7 and/or B.1.351 variants of Coronavirus. Allarity intends to continue to test stenoparib against various Coronavirus strains, beyond the current testing.

Steve Carchedi, CEO of the Company, said, “Allarity Therapeutics is committed to developing novel treatments that change the course of disease in areas of high unmet need. Our recent research and development work with stenoparib as a potential anti-viral treatment for COVID-19 is no exception. We are proud to be one of the very few companies leading development of a possible treatment for COVID-19 and for the B.1.1.7 and B.1.351 variants.  We are also proud to continue our priority clinical development of stenoparib as a potential best-in-class treatment for ovarian cancer. ”

Steen Knudsen, Ph.D., Chief Scientific Officer of the Company, further noted, “We are optimistic that the  additional anti-viral testing of stenoparib against the B.1.1.7 and B.1.351 variants will be as encouraging as previously seen with SARS-Cov-2 results.  As new variants of Coronavirus become more and more prominent, the need will increase for potential treatments for the many that may still be and become infected during this pandemic.”

Allarity Therapeutics plans to advance stenoparib into human clinical trials as a potential therapy for COVID-19 and is working opportunistically on securing funding to advance such trials.  In addition to investigating whether stenoparib has therapeutic potential as a possible treatment of SARS-CoV-2, including lineages B.1.1.7 and B.1.351, Allarity Therapeutics is also currently evaluating stenoparib for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute (Boston, MA U.S.A.) using a DRP companion diagnostic to guide patient enrollment and improve therapeutic outcome. Stenoparib is a novel small molecule (oral), targeted inhibitor of Poly ADP-Ribose Polymerase (PARP), a key DNA damage repair enzyme active in cancer cells.